Jorveza - Dr Falk

Sign in

Some information on this website may be viewed only by healthcare professionals.
If you would like to enter this section then please register as a healthcare professional.
Dr Falk Pharma UK Ltd Privacy Policy can be found here.


Please note that our privacy policy has recently been updated. Click here to review the policy.


Please fill out your details below to register for our site for healthcare professionals.

Please specify your preferred contact email address
Please specify your password, which should be a minimum of 8 characters, including at least one number and one capital letter
Passwords do not match
Please specify your salutation
Please specify your name
Please specify your last name
Please specify your position
Please specify your interest
Please specify your institution
Please enter a post code
Post Code not found
Please specify your practice name
Please specify your practice address
Please specify your practice town
Please specify your practice post code
Please specify a valid mobile number
Please specify a valid number

Please confirm you are a UK/Ireland HCP

Please review the Dr Falk Pharma UK Ltd Privacy Policy before registering.

We assure you that we work hard to keep your personal data secure and will not share any details with a 3rd party without your explicit consent.

You will be given the opportunity to unsubscribe during every communication.

You can update your preference at any time by contacting



Jorveza® is an orodispersible tablet containing the topically acting corticosteroid budesonide. The formulation has been specifically developed for the targeted treatment of Eosinophilic Oesophagitis (EoE) and is the first and only oral steroid currently licensed in the UK and globally for this condition.

Discover more about Jorveza

When taken, the tablet is pressed to the roof of the mouth with the tip of the tongue. It dissolves slowly over a period of approximately two minutes, with a mild effervescent effect stimulating salivation as the tablet dissolves. With the patient continuously swallowing the saliva during this period, the active ingredient is transported to the inflamed mucosa where, due to the adhesive properties of saliva, it coats the oesophagus evenly.

In a large randomised, controlled clinical trial in EoE patients, Jorveza demonstrated high rates of clinical and histological remission and high patient tolerability, with few side effects. (Complete clinical and histological remission of the disease of 58% at six weeks and 85% at 12 weeks compared to 0% on placebo; (p<0.001).1

1 ‘Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial’, Alfredo J. Lucendo  et al, Gastroenterology 2019 (in press)

Prescribing Information (refer to full SmPC before prescribing).

Presentations: Jorveza 1mg and 0.5mg orodispersible tablets containing 1mg or 0.5mg of budesonide. Indications: treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Dosage: Induction of remission: one 1mg tablet taken twice daily (morning and evening) after a meal and immediately after removal of the tablet from the blister pack. Usual duration of induction treatment is 6 weeks. Extend up to 12 weeks for non-responding patients. Maintenance of remission: 0.5mg twice daily or 1mg twice daily depending on clinical need. A maintenance dose of 1mg twice daily is recommended for patients with long-standing disease history and/or high extent of esophageal inflammation in the acute disease state. Duration of maintenance treatment – to be determined by the treating physician. Administration: tablet is placed on tip of tongue and pressed to top of mouth then swallowed slowly without liquid or food and without chewing or swallowing undisintegrated. May take 2 to 20 minutes to disintegrate and swallow completely. Wait at least 30 minutes before eating, drinking or performing oral hygiene. Contra-indications: hypersensitivity to budesonide or any ingredient of the tablets. Warnings/precautions: infections – Suppression of inflammatory response and immune function increases susceptibility to infections and their severity which can be atypical or masked. Oral, oropharyngeal and esophageal candida infections occur at high frequency. Treat symptoms with topical or systemic anti-fungals. Jorveza treatment can continue. Chickenpox, herpes zoster and measles – can be more serious in patients treated with glucorticosteroids. Check vaccination status. Avoid exposure. Vaccines – avoid co-administration of live vaccines and glucocorticosteroids. The antibody response to other vaccines may be diminished. Special populations – monitor patients with tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, cataract, family history of diabetes, family history of glaucoma. Systemic effects of glucocorticosteroids may occur, depending on duration of treatment, concomitant and previous glucocorticosteroid treatment and individual sensitivity. Patients with reduced liver function – an increased systemic availability of budesonide may be expected, with increased risk of adverse reactions. Patients with hepatic impairment should not be treated. Not recommended for use in patients with severe renal impairment. Angioedema – treatment should be stopped if signs of angioedema are observed. Visual disturbance – patients with blurred vision or other visual disturbances should be considered for referral to an ophthalmologist. Causes may include cataract, glaucoma or central serous chorioretinopathy resulting from corticosteroid use. Others – glucocorticosteroids may cause suppression of the hypothalamic–pituitary–adrenal (HPA) axis and reduce the stress response. When patients are subject to surgery or other stresses, supplementary systemic glucocorticosteroid treatment is therefore recommended. Concomitant treatment with ketoconazole or other CYP3A4 inhibitors should be avoided. Serological testing – adrenal function may be suppressed by budesonide so an ACTH stimulation test for diagnosing pituitary insufficiency might show false (low) results. Sodium – contains 52 mg of sodium per daily dose. Interactions: CYP3A4 inhibitors – concomitant treatment with ketoconazole or other potent CYP3A inhibitors including grapefruit juice should be avoided to reduce the risk of systemic side effects unless the benefit outweighs the risk. Such treatment should be monitored. Oestrogens, oral contraceptives – may elevate plasma concentrations and enhance effects of glucocorticosteroids. Concomitant intake of low-dose combination oral contraceptives has not shown this effect. Cardiac glycosides – action of glycoside can be potentiated by potassium deficiency – a potential and known adverse reaction of glucocorticoids. Saluretics – potassium excretion can be enhanced and hypolalaemia aggravated. Use in pregnancy should be avoided unless there are compelling reasons for therapy. Breast-feeding – budesonide is excreted in human milk. The benefit of breast feeding for the child and the benefit of therapy for the woman should be assessed. Fertility – there are no data on the effect of budesonide on human fertility. Undesirable effects: fungal infections in the mouth, pharynx and the oesophagus were the most frequently observed adverse reactions in clinical studies. Long term treatment did not increase the rate. Adverse reactions and frequencies: Very common: esophageal candidiasis, oral and/or oropharyngeal candidiasis, Common: sleep disorder, headache, dysgeusia, dry eyes, gastroesophageal reflux disease, nausea, oral paraesthesia, dyspepsia, upper abdominal pain, dry mouth, glossodynia, tongue disorder, oral herpes, fatigue, blood cortisol decreased. Uncommon: nasopharyngitis, pharyngitis, angioedema, , anxiety, agitation, dizziness, , hypertension, cough, dry throat, oropharyngeal pain, abdominal pain, abdominal distension, , dysphagia, erosive gastritis, gastric ulcer, lip edema, gingival pain, rash, urticaria, sensation of foreign body, osteocalcin decreased, weight increased. . Other (class) effects with unknown frequency that may occur: increased risk of infection, Cushing’s syndrome, adrenal suppression, growth retardation in children, hypokalaemia, hyperglycaemia, depression, irritability, euphoria, psychomotor hyperactivity, aggression, pseudotumor cerebri including papilloedema in adolescents, glaucoma, cataract (including subcapsular cataract), blurred vision, central serous chorioretinopathy (CSCR), increased risk of thrombosis, vasculitis (withdrawal syndrome after long-term therapy), duodenal ulcers, pancreatitis, constipation, allergic exanthema, petechiae, delayed wound healing, contact dermatitis, ecchymosis, muscle and joint pain, muscle weakness and twitching, osteoporosis, osteonecrosis, malaise. Legal category: POM. Cost: 1mg – pack of 90 – £323; 0.5mg – pack of 60 – £214.80. Not currently available in Ireland. Product licence holder: Dr. Falk Pharma GmbH. Product licence number: IE/NI: 1mg: EU/1/17/1254/004, 0.5mg: EU/1/17/1254/008. GB: 1mg: PLGB08637/0030; 0.5mg: PLGB08637/0032. Date of preparation: February 2023.

Further information is available on request.

Adverse events should be reported. In the UK visit In Ireland: Adverse events should also be reported to Dr Falk Pharma UK Ltd on or 0044 (0)1628 536600.


Summary of Product Characteristics (SmPC)

For further information, the Summary of Product Characteristics (SmPC) is available below.

This information on the following pages is intended only for UK and Irish residents who have been prescribed either Budenofalk, Salofalk, Ursofalk or Jorveza.